Effect of SB 217242 on hypoxia-induced cardiopulmonary changes in the high altitude-sensitive rat

Pulmonary Pharmacology and Therapeutics

Volumn 12, Issue 1, 1999, Pages 13-26

  Underwood, D C ^a   Bochnowicz, S ^a   Osborn, R R ^a   Luttmann, M A ^a   Louden, C S ^a,b   Hart, T K ^a,b   Elliott, J D ^a,c   Hay, D W P ^a  

^a Department of Pulmonary Pharmacology ^*  (United States)

^b Safety Assessment   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

A 192621; Endothelin receptor antagonists; Endothelin 1; ET(A) receptors; ET(B) receptors; Hypoxia; Pulmonary artery; Pulmonary hypertension; Right ventricular hypertrophy; SB 217242; SB 247083

Indexed keywords

4 (1,3 BENZODIOXOL 5 YL) 1 [(2,6 DIETHYLPHENYL)CARBAMOYLMETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; CARBACHOL; ENDOTHELIN; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; PHENYLEPHRINE; POTASSIUM CHLORIDE; SB 247083; UNCLASSIFIED DRUG;

ALTITUDE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY DILATATION; ARTERY OCCLUSION; ARTICLE; BLOOD LEVEL; CARDIOPULMONARY HEMODYNAMICS; CONTROLLED STUDY; DRUG POTENCY; HEART LEFT VENTRICLE MASS; HEART RIGHT VENTRICLE; HYPOXIA; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG ARTERY PRESSURE; MALE; NONHUMAN; OSMOTIC PUMP; PRESSOR RESPONSE; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; VASCULAR ENDOTHELIUM;

EID: 0033081805     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.1999.0158     Document Type: Article

References (47)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, YAzaki Y, Goto K, Masaki T. A novel vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
2. Stewart D J, Levy R D, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of diseases? Ann Intern Med 1991; 114: 464-469.
3. Giaid A, Yanagisawa M, Langleben D, Michel R P, Levy R, Shennib H, Kimura S, Masaki T, Duguid W P, Stewart D J. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739.
4. Hay D W P, Goldie R G. Role of endothelin in pulmonary diseases. In: Gulati A, ed. Endothelin: Role in Health and Disease. Amsterdam: Harwood Academic, 1995: 251-273.
5. Michael J R, Markewitz B A. Endothelins and the lung. Am J Respir Crit Care Med 1996; 154: 555-581.
6. Zapol W M, Snider M T. Pulmonary hypertension in severe acute respiratory failure. N Engl J Med 1977; 296: 476-480.
7. MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease, state-of-the-art: Parts 1 and 2. Am J Respir Crit Care Med 1994; 150: 833-852; 1158-1168.
8. Cody R J, Halas G J, Binkley P F, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85: 504-509.
9. Reid L M. The pulmonary circulation: Remodeling in growth and disease. Am Rev Respir Dis 1979; 119: 531-546.
10. Grover R F, Vogel J H K, Averill K, Blount S G. Pulmonary hypertension. Individual and species variability relative to vascular reactivity. Am Heart J 1963; 66: 1-3.
11. Rabinovitch M, Gamble W, Nadas A S, Miettinen O S, Reid L. Rat pulmonary circulation after chronic hypoxia: Hemodynamic and structural features. Am J Physiol 1979; 236: H818-H827.
12. Thompson B T, Hassoun P M, Kradin R L, Hales C A. Acute and chronic hypoxic pulmonary hypertension in guinea pigs. Am J Physiol 1989; 66: 920-928.
13. Elton S, Oparil S, Taylor G R, Hicks P H, Yang R H, Jin H, Chen Y F. Normobaric hypoxia stimulates endothelin-1 gene expression in the rat. Am J Physiol 1992; 263: R1260-R1264.
14. A-receptor antagonist, attenuates hypoxic pulmonary hypertension in rats. Am J Physiol 1994; 266: H1327-H1331.
15. A-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rats. Am J Physiol 1995; 269: L690-L697.
16. Oparil S, Chen S J, Meng Q C, Elton T S, Yano M, Chen Y F. Endothelin-a receptor antagonist prevents acute hypoxia-induced pulmonary hypertension in the rat. Am J Physiol 1995; 268: L95-L100.
17. Chen S J, Chen Y F, Opgenorth T J, Wessale J L, Meng Q C, Durand J, DiCarlo V S, Oparil S. The orally active nonpeptide endothelin A-receptor antagonist prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats. J Cardiovasc Pharmacol 1997; 29: 713-725.
18. Underwood D C, Bochnowicz S, Osborn R R, Luttmann M A, Hay D W P. Non-peptide endothelin receptor antagonists. X: Inhibition of endothelin-1-and hypoxia-induced pulmonary pressor responses in the guinea pig by the endothelin receptor antagonist, SB 217242. J Pharmacol Exp Ther 1997; 283: 1130-1137.
19. Ou L C, Smith R P. Probable strain differences of rats in susceptibilities and cardiopulmonary responses to chronic hypoxia. Respir Physiol 1983; 53: 367-377.
20. Hill N S, Ou L C. The role of pulmonary vascular responses to chronic hypoxia in the development of chronic mountain sickness in rats. Respir Physiol 1984; 58: 171-185.
21. Hill N S, Ou L C, Thron C D, Smith R P. Time course of cardiopulmonary responses to high altitude in susceptible and resistant rat strains. Respir Physiol 1987; 70: 241-249.
22. Underwood D C, Bochnowicz S, Osborn R R, Louden C S, Hart T K, Ohlstein E H, Hay D W P. Chronic hypoxia-induced cardiopulmonary changes in three rat strains: Inhibition by the ET receptor antagonist, SB 217242. J Cardiovasc Pharmacol 1998; 31: S453-S455.
23. Ohlstein E H, Nambi P, Lago A, Hay D W P, Beck G, Fong K-L, Eddy E P, Smith P, Ellens H, Elliott J D. Non-peptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist. J Pharmacol Exp Ther 1996; 276: 609-615.
24. A-selective antagonist SB 247083. J Cardiovasc Pharmacol 1998; 31 (Suppl 1): S273-S276.
25. Douglas S A. Clinical development of endothelin receptor antagonists. Trends Pharmacol Sci 1997; 18: 408-412.
26. Van Rossum J M. Cumulative dose-response curves. II: Techniques for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch Int Pharmacodyn 1963; 143: 299-330.
27. Bochnowicz S, Osborn R R, Hay D W P, Underwood D C. Hypoxia-induced pulmonary hypertension in an optimized environment for the guinea pig. Lab Animals 1997; 31: 347-356.
28. Ono S, Voelkel N F. PAF antagonists inhibit monocrotaline-induced lung injury and pulmonary hypertension. J Appl Physiol 1991; 71: 2483-2492.
29. Li H, Elton T S, Chen Y F, Oparil D. Increased endothelin receptor gene expression in hypoxic rat lung. Am J Physiol 1994; 266: L553-L560.
30. Xue C, Johns R A. Upregulation of nitric oxide synthesase correlates temporally with onset of pulmonary remodeling in hypoxic rat. Hypertension 1996; 28: 743-753.
31. 3H-thymidine by cells of the rat pulmonary arteries and alveolar wall. Am J Pathol 1979; 96: 51-70.
32. Warner T D, Elliot J D, Ohlstein E H. California dreamin' 'bout endothelin: Emerging new therapeutics. Trends Pharmacol Sci 1996; 17: 177-204.
33. Hay D W P, Hubbard W C, Luttmann M, Undem B J. Endothelin receptor subtypes in guinea-pig and human pulmonary tissues. Br J Pharmacol 1993; 110: 1175-1183.
34. MacLean M R, McCulloch K M, Baird M. Effects of pulmonary hypertension on vasoconstriction responses to endothelin-1 and sarafotoxin s6c and on inherent tone in rat pulmonary arteries. J Cardiovasc Pharmacol 1995; 26: 822-830.
35. Adnot S, Raffestin B, Eddahibi S, Braquet P, Chabrier P E. Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest 1991; 87: 155-162.
36. Bialecki R A, Fisher C S, Murdoch W W, Barthlow H G, Stow R B, MAllamaci M, Rumsey W. Hypoxic exposure time dependently modulates endothelin-induced contraction of pulmonary artery smooth muscle. Am J Physiol 1998; 18: L552-L559.
37. Feletou M, Girard V, Canet E. Different involvement of nitric oxide in endothelium-dependent relaxation of porcine pulmonary artery and vein: Influence of hypoxia. J Cardiovasc Pharmacol 1995; 25: 665-673.
38. Ryan U S, Zhong R, Hates B A, Visner G, Sauther M L. Regulation of endothelin-1 expression in normal and transfected endothelial cells. J Cardiovasc Pharmacol 1993; 22: S38-S41.
39. Kourembanas S, McQuillan L P, Leung G K, Faller D V. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 1993; 92: 99-104.
40. Goligorsky M S, Tsukahara H, Magazine H, Andersen T T, Malik A B, Bahou W F. Termination of endothelin signaling: Role of nitric oxide. J Cell Physiol 1994; 158: 485-494.
41. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214-221.
42. Markewitz B A, Kohan D E, Micheal J R. Hypoxia decreases endothelin-1 synthesis by rat lung endothelial cells. Am J Physiol 1995; 269: L215-L220.
43. Cherniak N S, Altmose M D. Diagnosis of chronic obstructive pulmonary disease. In: Leff A R, ed. Pulmonary and Critical Care Pharmacology and Therapeutics. New York: McGraw-Hill, 1996: 813-820.
44. MacLean M R, McCulloch K M, Baird M. ETA-and ETB-mediated vasoconstriction in rat arteries and arterioles. J Cardiovasc Pharmacol 1994; 23: 838-845.
45. B receptors in rats. Biochem Biophys Res Commun 1994; 199: 1461-1465.
46. Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, Schmitt R, Jones R, Bertel O. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346: 732-736.
47. B blockade on et-1-induced constriction in perfused rat lungs. Am J Physiol 1995; 269: L668-L672.